658 related articles for article (PubMed ID: 10470093)
1. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
2. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
[TBL] [Abstract][Full Text] [Related]
3. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
Grant S; Turner AJ; Bartimole TM; Nelms PA; Joe VC; Jarvis WD
Oncol Res; 1994; 6(2):87-99. PubMed ID: 7949469
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
[TBL] [Abstract][Full Text] [Related]
5. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
6. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ
Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875
[TBL] [Abstract][Full Text] [Related]
7. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
Tanaka M; Kimura K; Yoshida S
Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
[TBL] [Abstract][Full Text] [Related]
9. Antileukemic activity studies and cellular pharmacology of the analogues of 2-hydroxy-1H-isoindole-1,3-dione (HISD) alone and in combination with cytosine arabinoside (ara-C) against human leukemia cells CEM/0.
Nandy P; Lien EJ; Avramis VI
Acta Oncol; 1994; 33(8):953-61. PubMed ID: 7818931
[TBL] [Abstract][Full Text] [Related]
10. Time sequential expression of markers of apoptosis induced by 1-beta-D-arabinofuranosylcytosine in human T-lymphoblastic leukemia CCRF-CEM cells.
Badran A; Iwasaki H; Wano Y; Kishi S; Ueda T
Anticancer Res; 2001; 21(3B):1987-95. PubMed ID: 11497288
[TBL] [Abstract][Full Text] [Related]
11. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
Nandy P; Periclou AP; Avramis VI
Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
[TBL] [Abstract][Full Text] [Related]
12. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Fritzer-Szekeres M; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1541-4. PubMed ID: 15571294
[TBL] [Abstract][Full Text] [Related]
13. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis.
Chitambar CR; Wereley JP
Cancer Res; 1995 Oct; 55(19):4361-6. PubMed ID: 7671248
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
Chan TC
Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
16. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
Horvath Z; Saiko P; Illmer C; Madlener S; Hoechtl T; Bauer W; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Exp Hematol; 2005 Mar; 33(3):329-35. PubMed ID: 15730856
[TBL] [Abstract][Full Text] [Related]
17. N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine.
Saiko P; Ozsvar-Kozma M; Bernhaus A; Jaschke M; Graser G; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Int J Oncol; 2007 Nov; 31(5):1261-6. PubMed ID: 17912455
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3'-C-methyladenosine in leukaemia cells.
Meli M; Tolomeo M; Grifantini M; Mai A; Cappellacci L; Petrelli R; Rotili D; Ferro A; Saiko P; Szekeres T; Dusonchet L
Int J Oncol; 2011 May; 38(5):1427-36. PubMed ID: 21318222
[TBL] [Abstract][Full Text] [Related]
19. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
20. Atypical nuclear apoptosis downstream to caspase-3 activation in ara-C treated CCRF-CEM cells.
Badran A; Iwasaki H; Inoue H; Ueda T
Int J Oncol; 2003 Mar; 22(3):517-22. PubMed ID: 12579303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
